Alcestobart

Phase 2Small molecule

BeiGene

Alcestobart is one of 34 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

PORTRAZZA

Eli Lilly

Preclinical

8 2

Lenvima

Eisai

Preclinical

6 3

Ofev

Boehringer Ingelheim

Preclinical

7 4

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 5

Alcestobart

BeiGene

Phase 2

1 6

Remeron

OOrganon and Co

Preclinical

1 7

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

REGN2810

1 10

Vidaza

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal Cancer

NCT05609370

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Completed· BeiGene logo

BeiGene·Phase 2·NCT05577702·121 enrolled

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1 trial

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Active, not recruiting· BeiGene logo

BeiGene·Preclinical·NCT05609370·113 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Alcestobart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alcestobart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alcestobart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeiGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BeiGene

Alcestobart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News